Following his presentation at the EAACI annual meeting, we were delighted to talk with Prof. Dr. Philippe Gevaert (University of Ghent, Belgium) about targeted endotype therapeutics in severe airway disease.
1. What are the major unmet needs in the treatment of severe airway disease? (0:04)
2. Could you give is a brief overview of the role of endotypes in airway disease? (1:20)
3.What have been the most promising endotype-driven approaches to date? (3:10)
4.What other emerging therapeutic targets would you like to highlight? (4:25)
5. What are the major challenges to be overcome before endotype-driven therapies can be implemented in routine clinical practice? (6:26)
Speaker disclosure: Philippe Gevaert has served as a speaker and advisor for Ablynx, Argenx, Astra Zeneca, Sanofi, Novartis, Regeneron, Genentech, ALK and Stallergenes-Greer
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EAACI Digital Congress 2020.
Share this Video
Related Videos In Chronic Cough
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
James Wingfield Digby, ERS 2022: Low-dose Opiates for Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!